• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

New Exec Shake-Up at Valeant


August 09, 2016

Valeant Pharmaceuticals International, Inc. (Laval, Quebec) has announced a series of leadership and organizational changes. 

Christina Ackermann was named Executive Vice President and General Counsel. Ms. Ackermann has served in various legal roles at the Novartis group of companies for the past 14 years. Scott Hirsch also joined Valeant as Senior Vice President, Business Strategy and Communications. He joins from Citadel Investment Group.

The company also announced that Laurie Little, who has led Valeant's Investor Relations and Public Relations functions for the past nine years, will be leaving the company in the coming months and that Pavel Mirovsky, President and General Manager, Europe will retire later this year.

The company has also expanded the roles of key senior leaders Dr. Ari Kellen, Anne Whitaker and Tom Appio.

Related Videos